As of December 2014, Novozymes had roughly 57,000 shareholders, of whom ~99% were private investors, mainly in Denmark. Twenty institutional shareholders, including Novo A/S, owned approximately 40% of the B stock. Investors outside Denmark hold approximately 65% of the B common stock.
As of December 2014 Novo A/S held 26% of the total outstanding common stock and controlled 70% of the votes through its holding of the A common stock and 27,779,900 B shares. The figures related to the number of votes do not take into account treasury shares (own shares) held by Novozymes. Novo A/S is wholly owned by the Novo Nordisk Foundation, and so Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Hellerup, Denmark.
Only two shareholders, Novo A/S and Baillie Gifford & Co., currently hold more than 5% of the total common stock.